Rege Nephro Co., Ltd. (Headquarters: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka ; “our company”) is pleased to announce its selection for the incubator program “Bayer Co.Lab Connect*”, provided by Bayer.

The “Bayer Co.Lab Connect” program aims to invigorate Japan’s life sciences ecosystem by providing access to the global Bayer Co.Lab portfolio and the tools, networks, and resources needed to establish a foothold in the U.S. from Bayer Co.Lab Cambridge (US). This initiative promotes collaboration in research, development, and business. In June 2025, Rege Nephro is invited to an event in Boston, US, held in conjunction with the BIO International 2025, representing Japan and delivering the Winner’s speech.

Bayer Co.Lab Connect： https://colab.bayer.com/en/page/co-lab-connect-en

We are truly honored by our selection for the “Bayer Co.Lab Connect” program. This valuable opportunity represents a crucial stepping stone for our company as we look towards global market expansion. We will continue to leverage our cutting-edge technology and expertise to pursue innovations that contribute to solving critical societal challenges.